Precision Biosciences: Still Swinging And Finally Drawing Blood [Seeking Alpha]
Precision BioSciences, Inc. (DTIL)
Last precision biosciences, inc. earnings: 11/12 07:15 am
Check Earnings Report
Company Research
Source: Seeking Alpha
PBGENE-HBV shows compelling early efficacy and safety, positioning DTIL for a potential breakthrough in functional cures for chronic hepatitis B. DTIL maintains a 2/5 conviction rating due to technical weakness, competitive risks, and the need for cleaner bullish signals before adding to positions. Recent $75M raise extends funding into 2028, supporting key catalysts for PBGENE-HBV, PBGENE-DMD, and ECUR-506 without immediate dilution concerns. oakstudio22/iStock via Getty Images Back in 2023, I covered Precision BioSciences ( DTIL ) when the company was posting positive updates across their gene-editing programs, yet the market shrugged its shoulders. The company's pipeline had programs that could be legitimate best-in-class, which were More on my IG service Thank you for reading my research on Seeking Alpha. If you want to learn even more about my method and how I discover these investment opportunities, please check out my subscription marketplace service, Compounding H
Show less
Read more
Impact Snapshot
Event Time:
DTIL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DTIL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DTIL alerts
High impacting Precision BioSciences, Inc. news events
Weekly update
A roundup of the hottest topics
DTIL
News
- Precision BioSciences (NASDAQ:DTIL) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Precision BioSciences Announces Presentation of Clinical Data from the ELIMINATE-B Trial at HEP-DART 2025 [Yahoo! Finance]Yahoo! Finance
- Precision BioSciences Announces Presentation of Clinical Data from the ELIMINATE-B Trial at HEP-DART 2025Business Wire
- Precision BioSciences, Inc. (DTIL) Discusses ARCUS Platform Progress and ELIMINATE-B Clinical Trial Update for Chronic Hepatitis B Transcript [Seeking Alpha]Seeking Alpha
- Precision BioSciences Announces $75 Million Offering of Common Stock, Pre-Funded Warrants and WarrantsBusiness Wire
DTIL
Earnings
- 11/3/25 - Miss
DTIL
Sec Filings
- 11/14/25 - Form SCHEDULE
- 11/12/25 - Form 8-K
- 11/12/25 - Form 424B5
- DTIL's page on the SEC website